نتائج البحث - Ursula Vehling‐Kaiser

  • يعرض 1 - 18 نتائج من 18
تنقيح النتائج
  1. 1
    Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

    Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer حسب Florian Lordick, Sylvie Lorenzen, J. Stollfuß, Ursula Vehling‐Kaiser, Frank Kullmann, Marcus Hentrich, R. Zumschlinge, H Dietzfelbinger, Jutta Thoedtmann, Michael Hennig, T. Seroneit, Rainer Bredenkamp, Justus Duyster, C. Peschel

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut)

    Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut) حسب Dominik Paul Modest, Christoph Schulz, Ludwig Fischer von Weikersthal, D. Quietzsch, Jobst C. von Einem, Andreas Schalhorn, Ursula Vehling‐Kaiser, Rüdiger P. Laubender, Clemens Gießen, Sebastian Stintzing, Volker Heinemann

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

    FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumou... حسب Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Ursula Vehling‐Kaiser, Elke Jäger, Tobias Heintges, Claude Stoll, Clemens Gießen, Dominik Paul Modest, Jens Neumann, Andreas Jung, Thomas Kirchner, Werner Scheithauer, Volker Heinemann

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors

    NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predomi... حسب Christoph Schulz, Frank Kullmann, Volker Kunzmann, Martin Fuchs, Michael Geißler, Ursula Vehling‐Kaiser, Heribert Stauder, Axel Wein, Salah‐Eddin Al‐Batran, Thomas Kubin, Claus Schäfer, Sebastian Stintzing, Clemens Gießen, Dominik Paul Modest, Karsten Ridwelski, Volker Heinemann

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

    Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer حسب Volker Heinemann, D. Quietzsch, Frank Gieseler, Michael Gonnermann, H Schönekäs, A. Rost, Horst Neuhaus, Caroline Haag, Michael Clemens, Bernard Heinrich, Ursula Vehling‐Kaiser, Martin Fuchs, Doris Fleckenstein, Wolfgang Gesierich, D. Uthgenannt, Hermann Einsele, Axel Holstege, Axel Hinke, Andreas Schalhorn, Ralf Wilkowski

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal Cancer

    Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumo... حسب Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, S. Held, Markus Möhler, Andreas Jung, Thomas Kirchner, Volker Heinemann

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

    Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306) حسب Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christoph Kahl, G. Seipelt, Frank Kullmann, Werner Scheithauer, Markus Moehler, Julian Walter Holch, Jobst C. von Einem, Swantje Held, Volker Heinemann

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

    EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 حسب Stefan Boeck, Andreas Jung, Rüdiger P. Laubender, Jens Neumann, Rosalind Egg, Clara Goritschan, Ursula Vehling‐Kaiser, C Winkelmann, Ludwig Fischer von Weikersthal, Michael Clemens, Thomas Gauler, Angela Märten, Stefan Klein, G. Kojouharoff, Meagan Barner, Michael Geißler, Tim F. Greten, Ulrich Mansmann, Thomas Kirchner, Volker Heinemann

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

    Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK... حسب Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling‐Kaiser, Martina Stauch, Holger G. Hass, H Dietzfelbinger, Daniel Oruzio, Stefan Klein, Klaus Zellmann, Thomas Decker, Mathias Schulze, Wolfgang Abenhardt, Gerhard Puchtler, Herbert Kappauf, J. Mittermüller, C. Haberl, Andreas Schalhorn, Andreas Jung, Sebastian Stintzing, Volker Heinemann

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population

    Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population حسب Sebastian Stintzing, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, C. Lerchenmueller, Christoph Kahl, G. Seipelt, Frank Kullmann, Werner Scheithauer, Swantje Held, Clemens Gießen, Markus Moehler, A. Jagenburg, Andreas Jung, Thomas Kirchner, Volker Heinemann

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

    Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3... حسب Volker Heinemann, Ursula Vehling‐Kaiser, Dirk Waldschmidt, E. Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, G. Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael Clemens, Michael Geißler, Tim F. Greten, Susanna Hegewisch‐Becker, Oleg Rubanov, Gerold Baake, Thomas Höhler, Yon Ko, Andreas Jung, Sascha Neugebauer, Stefan Boeck

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

    Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy:... حسب Jobst C. von Einem, Volker Heinemann, Ludwig Fischer von Weikersthal, Ursula Vehling‐Kaiser, Martina Stauch, Holger G. Hass, Thomas Decker, Stefan Klein, Swantje Held, Andreas Jung, Thomas Kirchner, Michael Haas, Julian Walter Holch, Marlies Michl, Philipp Aubele, Stefan Boeck, Christoph Schulz, Clemens Gießen, Sebastian Stintzing, Dominik Paul Modest

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

    The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia حسب Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al‐Sawaf, Julia von Tresckow, Anna‐Maria Fink, Karl‐Anton Kreuzer, Ursula Vehling‐Kaiser, Eugen Tausch, Lothar Müller, Michael J. Eckart, Rudolf Schlag, W. Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens‐Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

    Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial حسب Othman Al‐Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böettcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia von Tresckow, Ursula Vehling‐Kaiser, Tobias Gaska, Clemens‐Martin Wendtner, Bjoern Chapuy, Kirsten Fischer, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Philipp B. Staber, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

    Long Term Follow‐up Data and Health‐Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) حسب Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens‐Martin Wendtner, Wolfram Klapper, Karl‐Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek, Barbara Eichhorst

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Treatment of Older Patients with Mantle-Cell Lymphoma

    Treatment of Older Patients with Mantle-Cell Lymphoma حسب Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine, Jan Walewski, Marek Trněný, Carsten Geisler, Stephan Stilgenbauer, Catherine Thiéblemont, Ursula Vehling‐Kaiser, Jeanette K. Doorduijn, Bertrand Coiffier, Roswitha Forstpointner, Hervé Tilly, Lothar Kanz, Pierre Feugier, Michał Szymczyk, Michael Hallek, Stephan Kremers, G. Lepeu, Laurence Sanhès, Josée M. Zijlstra, Réda Bouabdallah, Pieternella J. Lugtenburg, Margaret Macro, Michael Pfreundschuh, Vít Procházka, Francesco Di Raimondo, Vincent Ribrag, M. Uppenkamp, Marc André, W. Klapper, W. Hiddemann, Michael Unterhalt, Martin Dreyling

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

    Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combin... حسب Peter Gibbs, Volker Heinemann, Navesh Sharma, Julien Taı̈eb, Jens Ricke, Marc Peeters, Michael Findlay, Bridget A. Robinson, Christopher Jackson, Andrew Strickland, Val Gebski, Mark Van Buskirk, Huaqing Zhao, Guy van Hazel, Michael D. Brown, Matthew Burge, Giuseppe Cardaci, Stephen Clarke, Paul Eliadis, Tom Ferguson, Vinod Ganju, Peter Gibbs, Guy van Hazel, Philip E. James, Christos S. Karapetis, Winston Liauw, Gavin Marx, Marco Matos, Louise Nott, Nick Pavlakis, Alex Powell, Timothy Price, David Ransom, Eva Segelov, Jenny Shannon, Nimit Singhal, Andrew Strickland, Euan Walpole, Michel Craninx, Thierry Delaunoit, Amélie Deleporte, Michel Ferrante, Karen Geboes, Alain Hendlisz, Koen Hendrickx, Marc De Man, Els Monsaert, Veerle Moons, Marc Peeters, Marc Polus, Éveline Boucher, Jacques Balosso, P. Chevallier, Samy Louafi, Marc Pracht, Christine Rebischung, Denis Smith, Julien Taı̈eb, Eric Terrebonne, Harald-Robert Bruch, Gerald Gehbauer, Volker Heinemann, Thomas Helmberger, Yon-Dschun Ko, H. Kröning, Frank Lammert, Arnd Nusch, Stefan Pluntke, Karsten Ridwelski, Jorge Riera‐Knorrenschild, Hanno Riess, Jorge Ramon Riera, Jens Ricke, Tilmann Sauerbruch, Klemens Scheidhauer, Oliver Stötzer, Klaus Tatsch, Ursula Vehling‐Kaiser, Thomas Vogl, Alex Beny, Ravit Geva, Einat Shacham‐Shmueli, Salomon M. Stemmer, Thomas Tichler, Ido Wolf, Bruna Angelelli, Andrea Martoni, Michael Findlay, Richard Isaacs, Anne O’Donnell‐Luria, D Díaz Pérez, Bridget A. Robinson, Javier Rodríguez, Ruth Vera, Pradip Amin, Daniel Bloomgarden, James T. Bui, James Carlisle, Seungjean Chai, Yi‐Jen Chen

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

    Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial حسب Judith Trotman, Sally F. Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter Fingerle‐Rowson, Jiawen Zhu, Tina Nielsen, Deniz Şahin, Wolfgang Hiddemann, Robert Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine S. Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van Eygen, Randeep Sangha, Pam McKay, Jonathan Wilson, Richard van der Jagt, Daryl Roitman, Marek Trněný, Jiřı́ Mayer, Katell Le Dû, Philippe Solal‐Céligny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange‐Krex, Axel Florschütz, Hans‐Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Heß, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling‐Kaiser, Martin Hoffmann, Zita Borbényi, M. Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Canales, Francisco Javier Peñalver Párraga, Alfonso Soler Campos, Juan‐Manuel Sancho, José Antonio Márquez Navarro, Carlos Grande García, Herman Nilsson‐Ehle, Helen O. McCarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin J.S. Dyer, Ruth Pettengell, John Seymour, John G. Gribben, Saad Al‐Ismail, F. N. Al‐Refaie, Norbert Blesing, Christopher Macnamara, Ann O’Callaghan, Andrew Haynes, George Follows, Roderick J. Johnson, David Cunningham, Kristian M. Bowles, Graham P. Collins, Eve Gallop‐Evans, Stephen Robinson, Chezhian Subash

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: